C57BL/6J小鼠超数排卵的研究

目的　确定C57BL 6J小鼠超排的最佳激素剂量和最合适的注射间隔时间 ,提高超排率。方法　 40只C57BL 6J雌鼠随机分为四组 ,分别用 5IU或 10IU的PMSG和HCG ,间隔 48h或 72h注射 ,比较排出卵母细胞的数量。结果　 5IU +5IU剂量的PMSG和HCG、间隔 48h注射组超排效果最好 ;8～ 10周龄雌鼠较 6～ 8周龄雌鼠超排效果好。结论　C57BL 6J小鼠超排的最佳激素剂量为 5IUPMSG +5IUHCG ,最合适的注射间隔时间为 48h ,处于繁殖期的雌鼠超排效果好。     

小鼠超数排卵优化试验方案研究

探讨建立一种适合贵州地区、高效、稳定的小鼠超数排卵优化方案。在饲养环境相同的基础上,对激素(PMSG, hCG)不同的剂量组合、注射间隔时间、小鼠周龄等影响因素进行了相关研究。试验结果表明:(1)平均采胚数量组间、平均异常胚组间与平均可用胚组间差异显著(p<0.05),注射10 IU的激素剂量组合获得受精卵最多,且异常胚最少,效果最佳。(2)第1、第2、第3组平均采胚数量组间差异显著(p<0.05),第1组与第2组平均可用胚组间差异不显著(p>0.05),但第1、2组与第3组差异显著(p<0.05),异常胚组间差异不显著(p>0.05),选择4周龄超排效果最佳。(3)第1、第2、第3组平均采胚数量、平均可用胚组间差异显著(p<0.05),平均异常胚组间差异不显著(p>0.05),PMSG,hCG间隔注射时间为48 h为最佳。     

不同激素和注射方式对家猫超排效果的比较

比较了PMSG／hCG和FSH／hCG两种方案以及PMSG的不同剂量和注射方式对家猫的超排效果的影响。用100IU的PMSG超排家猫所得到的排卵点数及平均每只猫获得的卵数显著低于200IU处理组或300IU处理组（P＜0．05）,但200IU处理组与300IU处理组之间的超排效果也无显著差异（P＞0．05）;用皮下注射200IU的PMSG或用肌肉注射200IU的PMSG对超排效果无差异（P＞0．05）;用200IU PMSG／200IU hCG和1.5mg FSH/200IU hCG两种方案对家猫超排,发现不论是每只猫的排卵点数、卵子获得数,还是卵子的第一极体排放率都没有显著差异（P＞0．05）。实验说明,PMSG的注射方式不影响对家猫的超排效果,用200IU的PMSG超排家猫是较适合的剂量,FSH和PMSG都可用于家猫的超排,但PMSG使用更为方便。     

不同激素和注射方式对家猫超排效果的比较

比较了PMSG hCG和FSH hCG两种方案以及PMSG的不同剂量和注射方式对家猫的超排效果的影响。用 1 0 0IU的PMSG超排家猫所得到的排卵点数及平均每只猫获得的卵数显著低于 2 0 0IU处理组或 30 0IU处理组 (P <0 0 5 ) ,但 2 0 0IU处理组与 30 0IU处理组之间的超排效果也无显著差异 (P >0 0 5 ) ;用皮下注射 2 0 0IU的PMSG或用肌肉注射 2 0 0IU的PMSG对超排效果无差异 (P >0 0 5 ) ;用 2 0 0IUPMSG 2 0 0IUhCG和 1 5mgFSH 2 0 0IUhCG两种方案对家猫超排 ,发现不论是每只猫的排卵点数、卵子获得数 ,还是卵子的第一极体排放率都没有显著差异 (P >0 0 5 )。实验说明 ,PMSG的注射方式不影响对家猫的超排效果 ,用 2 0 0IU的PMSG超排家猫是较适合的剂量 ,FSH和PMSG都可用于家猫的超排 ,但PMSG使用更为方便。     

不同剂量孕马血清促性腺激素超排处理对家兔卵巢组织形态和胚胎发育的影响

为了研究不同剂量的孕马血清促性腺激素（PMSG）对家兔（Oryctolagus cuniculus f. domesticus）超排后,卵巢组织形态和PMSG对早期胚胎体外发育的影响。将24只家兔分为对照组、50 IU、70 IU和90 IU组,每组6只,对照组不做处理,后3组分别注射50 IU、70 IU和90 IU PMSG和定量100 IU人绒毛膜促性腺激素（HCG）对家兔进行超排处理。解剖后测定卵巢形态和组织参数。利用注射器抽取5ml冲卵液,分别从左右输卵管冲取胚胎至培养皿中,转至细胞培养室对胚胎进行体外培养观察。结果显示,PMSG处理组与对照组相比,随着PMSG注射剂量的增大,家兔卵巢重及宽度和厚度均极显著增大（P<0.01）,卵巢长度显著增长（P<0.05）,卵巢表面充血,卵泡数增多;另外,随PMSG注射剂量的增大,次级卵泡及其卵母细胞直径、三级卵泡直径均呈减小趋势（P <0.01）,三级卵泡中卵母细胞直径呈增大趋势,与对照组相比差异显著（P <0.05）;三级卵泡的直径和卵泡的优势化率,70 IU组显著高于对照组及50 IU和90 IU组（P &l...     

环磷酰胺对长爪沙鼠精子畸形的影响

目的探讨环磷酰胺（CP）对长爪沙鼠精子畸形的影响。方法取长爪沙鼠随机分成正常对照组,CP组（低、中、高剂量组即剂量分别为20 mg/kg、30 mg/kg、40 mg/kg）,环磷酰胺经腹腔注射,连续注射5 d,药后30d麻醉沙鼠,剖腹取出两侧附睾制备精子悬液涂片,用甲醇固定10 min,用2%的伊红染色30 min,蒸馏水洗片,显微镜观察精子形态。结果低、中、高剂量组分别与正常对照组比较,长爪沙鼠精子畸形率差异极显著（P〈0.01）;低、中剂量组分别与高剂量组相比较,长爪沙鼠精子畸形率差异极显著（P〈0.01）;低剂量组与中剂量组比较,精子畸形率差异不显著（P〉0.05）。形态学观察显示：环磷酰胺对长爪沙鼠精子影响畸形类型主要为尾折叠、尾粗细/长短/扭曲和无钩。结论环磷酰胺对长爪沙鼠精子有一定的致畸率,且对长爪沙鼠精子尾部影响最大。在一定剂量内范围内,环磷酰胺对长爪沙鼠的精子致畸率无明显区别;当高于一定剂量,随着环磷酰胺用药剂量的增加,长爪沙鼠的精子致畸率也增加。     

利用超数排卵方法高效获取小鼠休眠胚胎

目的为提高小鼠休眠胚胎的制备效率,尝试用超数排卵方法获取小鼠休眠胚胎。方法超排小鼠在注射孕马血清促性腺激素(PMSG)后,按照是否注射抗孕马血清(anti-PMSG serum或A-PMSG)以及注射的不同时间分为5组:在母鼠合笼前注射A-PMSG、在母鼠见栓后注射A-PMSG、在见栓第四天卵巢摘除手术后注射A-PMSG、不注射A-PMSG的超排组和不超排组。结果见栓后注射抗PMSG组的平均出胚数(9.4枚/只)最高,显著高于其他实验组。结论常规超排处理结合注射抗PMSG血清法能有效提高小鼠休眠胚胎的回收率。     

体外重组的人促黄体素对小鼠早期胚胎发育的影响

为了研究人的重组促黄体素（r-hLH)对小鼠早期胚胎发育的作用,我们用一定剂量的r-hFSH(人促卵泡素,20IU）结合不同剂量的r-hLH（0－20IU）,或先与不同剂量r-hLH配比（5－20IU）,再与一定剂量,r-hLH（15IU）结合,对性成熟前的小鼠进行超数排卵;并对从其输卵管冲出的早期胚胎进行体外培养,通过观察这些早期胚胎体外发育情况,再与PMSG－hCG超排小鼠的早期胚胎体外培养结果进行比较。我们发现用重组激素处理的性成熟前小鼠,无论在平均冲胚数或桑囊率,囊胚率上,都以结合r-hLH或配比r-hLH的剂量为15IU时最好,但各重组激素处理组在桑囊率和囊胚率上都极显著低于PMSG－hCG对照组的相应指标。上述结果表明,r-hLH对小鼠早期胚胎的发育（尤其是囊胚的形成）有明显的抑制作用,且与r-hLH呈一定的剂量依赖性关系。     

尿激酶及其抑制物对未成年小鼠排卵的影响

利用未成年小鼠超数排卵方法,研究了纤溶酶原激活因子——尿激酶和它的抑制物——6氨基己酸对排卵的作用。实验结果表明:18日龄小鼠在注射PMSG和hCG条件下,增注尿激酶800U,排卵动物数及平均排卵数与对照组比较有显著性差异。如果仅用PMSG和尿激酶,不能引起动物排卵。21日龄小鼠在注射PMSG后再注射不同剂量hCG情况下增注尿激酶,平均排卵数均比相应对照组有显著性差异,但hCG注射量为l.25IU组,增注尿激酶后,实验组与对照组平均排卵数无显著性差异。用尿激酶抑制剂6氨基己酸可以有效抑制超数排卵的效果。实验结果提示,尿激酶只有在hCG存在条件下对小鼠排卵有促进作用,而尿激酶本身不具有诱发排卵的作用。     

链脲佐菌素诱导长爪沙鼠Ⅰ型糖尿病模型的实验研究

目的探讨链脲佐菌素(STZ)诱导长爪沙鼠Ⅰ型糖尿病模型的可能性,并观察模型动物早期肾脏损害情况。方法雄性长爪沙鼠96只,随机分为正常对照组(NC组)、模型组1(DM1组)、模型组2(DM2组),DM1及DM2组沙鼠分别一次性腹腔注射100 mg/kg、200 mg/kg STZ,NC组注射等量柠檬酸盐缓冲溶液。注射STZ后1、2、4、6周末,分别监测沙鼠一般情况,血糖、胰岛素等血清学指标和尿液指标,并处死沙鼠进行胰腺和肾脏组织的病理学检查。结果注射STZ 24 h后,DM2组及DM1组部分沙鼠逐渐出现典型的"三多一少"症状,随着病程的发展,DM2组沙鼠持续高血糖,DM1组沙鼠血糖值与NC组差异有显著性(P0.05),但有下降趋势;DM2组沙鼠胰岛素显著性降低(P0.05),其他血清学指标及尿液指标均显著性升高(P0.05),DM1组沙鼠各指标差异无显著性。DM2组沙鼠及DM1组少数沙鼠胰腺组织中可见胰岛β细胞减少、空泡样变性等变化,DM2组沙鼠肾脏组织中出现肾小球基质增多,毛细血管襻扩张等病变,DM1组沙鼠肾脏组织未见明显变化。结论 STZ 200 mg/kg可成功诱导长爪沙鼠Ⅰ型糖尿病模型,在病程早期沙鼠肾脏结构和功能已经发生改变。     

Estrous cycle stage-independent treatment of PMSG and hCG can induce superovulation in adult Wistar-Imamichi rats.

The estrous cycle influence on the number of ovulated eggs after injection of pregnant mare serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG) was investigated in 12, 18, and 24 weeks old adult female Wistar-Imamichi (WI) rats. PMSG (150 IU/kg) was injected at metestrus, diestrus, proestrus, or estrus, followed by hCG (75 IU/kg) 55 h later. Ovulation was induced at all ages and stages of the estrous cycle. The number of ovulated eggs was not affected by stage for similarly aged rats, however, the number of ovulated eggs obtained after treatment decreased with age. These results demonstrate that the PMSG/hCG treatment can induce ovulation at any stage of estrous cycle in WI rats and efficient superovulation at 12 weeks of age.     

Superovulation in immature and mature Chinese hamsters

Mature female Chinese hamsters ovulate an average of 8.8 ± 1.0 (mean ± SD) eggs per female in each estrous cycle. Superovulation can be induced in both immature and mature females by subcutaneous or intraperitoneal injections of pregnant mare serum gonadotropin (PMSG) and either human chorionic gonadotropin (hCG) or pituitary luteinizing hormone (PLH). The best superovulation in immature females was induced by the administration of 15 IU of PMSG followed 72 hr later by injection of 15 IU of hCG (about 25 eggs per female) or 0.2 mg (200 IU) PLH (about 46 eggs per female). Ovulation started about 13–15 hr after administration of hCG (or PLH) and was completed during the next 5–6 hr. Superovulation in mature females could be induced by injecting PMSG any day of the estrous cycle, but the best superovulation (about 39 eggs per female) was induced by injecting 15 IU of PMSG on day 1 (day of ovulation) followed by the injection of 0.4 mg of PLH 72 hr later. When immature females treated with the best superovulatory protocol were mated on the evening of PLH injection, only 5% of the eggs were found fertilized 50 hr after PLH administration. On the other hand, about 60% of the eggs were found fertilized in mature females mated following treatment with the best superovulatory protocol. The majority (83–85%) of superovulated eggs obtained from both immature and mature females were normally fertilized in vitro.     

Production of transgenic rats using young Sprague-Dawley females treated with PMSG and hCG.

The aim of this study was to examine the effects of gonadotrophin treatments on estrus synchronization and superovulation in young Sprague-Dawley (SD) rats that had not yet exhibited defined estrus cycles (5 to 7 weeks old), and to produce transgenic rats using these females as embryo donors and recipients. In Experiment 1, female rats were injected with PMSG and hCG (12.5, 25, 50 and 100 IU/kg each) and were mated with stud males. The reproductive performance of young rats were highest when PMSG and hCG at doses of 25 IU/kg each were injected (delivery rate 87.5%, nursing rate 92.9%). In Experiment 2, female rats were injected with PMSG and hCG (100, 150 and 300 IU/kg each) to induce superovulation. More eggs were recovered from the rats injected with PMSG and hCG at 150 and 300 IU/kg than from those treated with 100 IU/kg (33.4 and 41.3 vs. 13.3 eggs per female, respectively; p < 0.05). In Experiment 3, pronuclear-stage zygotes from 150 IU/kg PMSG/hCG-treated rats were used for microinjection of the fusion gene of bovine alpha S1-casein gene promoter and human growth hormone gene (2.8 kb), and the microinjected zygotes were transferred into the oviduct ampullae of the 25 IU/kg PMSG/hCG-treated rats. Seventeen transgenic rats were obtained from the 334 DNA-injected zygotes (5.1%). These results indicate that recipients and embryo donors for the production of transgenic rats can be prepared by the appropriate PMSG and hCG treatments of young SD rats, regardless of their estrus stages.     

Estrous stage- and animal age-independent superovulation in the BrlHan:WIST@Jcl(GALAS) rat.

In most strains of rats, the effects of treatment for the induction of superovulation show major strain differences and are strongly influenced by the stage of the estrous cycle. This study demonstrated, however, that superovulation was easily induced in Wistar strain Brl Han:WIST@Jcl(GALAS) rats by PMSG and hCG administration. To confirm the effects of such treatment, we studied age differences in egg collection efficiency. After superovulation was induced by intraperitoneal administration of 150 IU/kg PMSG and 75 IU/kg hCG given 48 h apart, the mean numbers of oocytes obtained from rats at 4, 8, 12, 20 and 28 weeks of age were 38.9, 33.5, 46.1, 26.9 and 21.3, respectively. No differences caused by the estrous stage at the PMSG administration were observed. In an embryo transfer experiment, fertilized eggs obtained from superovulated rats at each week of age showed equivalent viability until full-term to those from untreated rats. These results suggest that estrous stage-independent superovulation is effective not only in the pre-pubertal stage but also in adult rats.     

Rat embryo quality and production efficiency are dependent on gonadotrophin dose in superovulatory treatments

The present study was performed to optimize a superovulation protocol in rats in order to produce a large number of good-quality embryos suitable to develop rat embryonic stem (rES) cells. We first evaluated the ovulation kinetics of three rat strains: Wistar, Fisher and ACI/N. Animals (n=30 per strain) were treated with 50 IU of pregnant mare serum gonadotrophin (PMSG), and ovulation was induced with 50 IU of human chorionic gonadotrophin (hCG) 50 h apart. Next, we evaluated the dose-response curves of PMSG and hCG in Wistar rats in order to obtain the highest number of embryos. The parameters evaluated for superovulation efficiency were: percentage of mated females, percentage of pregnant females and the average number of embryos collected per female. The results of these experiments suggested that the best dose combination was 50 IU for each hormone. Subsequent experiments, again with Wistar rats, were designed to test which of four hormonal combination treatments (30/30, 30/50, 50/30, and 50/50 IU of PMSG/hCG) will produce the largest numbers of good-quality embryos. Embryo quality was evaluated by embryo development uniformity, embryo morphology, embryo survival in an in vitro culture and embryo ability to generate rES-like cells. Results from these experiments showed that 30/50 IU of PMSG/hCG was the treatment that induced the best embryo quality. In conclusion, our results indicated that, in Wistar rats, the most appropriate hormonal combination dose for superovulation protocols with high number of good-quality embryos was 30 IU of PMSG and 50 IU of hCG given 50 h apart. We are performing further studies with rES-like cells produced with the present methodology to evaluate if they are able to participate in the production of germ-line chimeras.     

Plasma levels of oestradiol-17 beta in the pre-puberal heifer treated to induce superovulation

The plasma concentrations of oestradiol-17β have been measured by radioimmunoassay in pre-puberal calves following treatments used to induce superovulation (PMSG/HCG and PMSG/FGA/HCG). Before treatment, in almost all animals, the concentrations of oestradiol-17β were different from zero (2 to 8 pg/ml). The highest concentrations were measured around 130 h. after the beginning of treatment, before ovulation (150 to 2050 pg/ml). The curves showing the changes in hormonal levels have the same form as those of follicular growth measured using morphological criteria. The two hormonal treatments resulted in similar oestradiol-17β concentrations.     

Fertilizability of Superovulated Eggs by Estrous Stage-independent PMSG/hCG Treatment in Adult Wistar-Imamichi Rats

We investigated the fertilization and developmental ability of superovulated eggs obtained from adult Wistar-Imamichi (WI) rats, by using pregnant mare serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG) treatment. Female WI rats, 11–13 weeks of age, were divided into four groups by estrous stage (metestrus [ME], diestrus [DE], proestrus [PE], or estrus [E]). PMSG (150 IU/kg) and hCG (75 IU/kg) were injected at an interval of 48 or 55 h and the female rats were mated with mature male rats. The ovulated eggs were collected 20, 24, and 27 h after hCG injection. Regardless of the estrous stage at the time of PMSG injection, the treated rats mated and ovulated similar to the untreated spontaneously ovulated rats (S group). Although the proportion of fertilized eggs in the E- and PE-treated groups was less than the S group 20 h after hCG injection, the proportion was not different among all treated and S groups 24 h after hCG injection. The proportion of fertilized eggs using in vitro fertilization and the proportion of offspring obtained from 2-cell stage embryo transfer did not differ among the treated and S groups. In comparison with PMSG/hCG-treated immature rats, mating and ovulation rate of adult rats were significantly higher. The proportion of fertilized eggs obtained from mated rats did not differ between immature and adult rats. These results demonstrate that adult WI rats are good egg donors for reproductive biotechnological studies using unfertilized or fertilized eggs.